

PT Mezei PS:
 XX NPI: 2001-374290/39.
 DR N-PSDB: AAB83866.
 XX
 PT Novel isolated human transmembrane, neuromedin peptide
 PT gonadotropin-like protein and interleukin-1 receptor antagonist
 PT proteins, useful for treating cancer, immune response disorder,
 PT metabolic function disorders
 PS
 PS Claim 1: Fig 3b: 138pp: English.
 XX
 CC The invention provides novel polypeptides (NOVY) selected from human
 CC transmembrane protein (NOVTRAM), neuromedin peptide (NOVNEUR),
 CC gonadotropin-like protein (NOVGON) and two interleukin-1 receptor
 CC antagonist proteins (NOVITRA A and B). The invention also provides
 CC methods in which a NOVY polypeptide, polynucleotide and antibody are
 CC used for the treatment of a broad range of diseases.
 CC pathological states. NOVTRAM can be used to treat reproductive illness
 CC disorder such as cancer, immune response disorder, hematopoietic
 CC disorder, neurodegenerative disorder. NOVNEUR can be used to treat
 CC endocrine disorder, muscle disorder, neurologic disorder, cancers of
 CC central nervous system, breast, colon, ovary, kidney, prostate and
 CC thyroid. NOVGON can be used to treat reproductive development disorder,
 CC metabolic function disorder and melanoma. NOVITRA A and B can be used
 CC for the treatment of cancer, immune response disorder, hematopoietic
 CC disorder, immune regulation disorder, septic shock, stroke, diabetes,
 CC arthritis and cancer. The present sequence represents the NOVNEUR
 CC polypeptide.
 XX
 XX Sequence 112 AA:
 S0
 Query Match: 100.0%; Score 568; DB 22; Length 112;
 Best Local Similarity 100.0%; Pred. No. 8,7e-57;
 Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 1 MFGSLFALLAAGVPSLMDLPPRRSARNTIRVSRKLTMTGHPMKSKLSPSSSP 60
 Db 1 MFGSLFALLAAGVPSLMDLPPRRSARNTIRVSRKLTMTGHPMKSKLSPSSSP 60
 Oy 61 GAAPHRSAPROQRQASHDLGLILLKNAAGVLSRPAFOIQRRLVLOLQ 112
 Db 61 GAAPHRSAPROQRQASHDLGLILLKNAAGVLSRPAFOIQRRLVLOLQ 112
 Db 61 GTEPHSIRDTGRIGSHNDLIGILLIKALVASEPAPQIGYRFLVQLK 112
 RESULT 2
 AAB48078 standard; protein: 121 AA.
 XX ID AAB48078 standard; protein: 121 AA.
 XX AAB48078:
 XX 19-MAR-2001 (first entry)
 XX human extracellular signaling molecule (EXCS) (ID I440015CD1).
 XX
 XX Extracellular signaling molecule: EXCS; anti-inflammatory; human;
 XX immunosuppressive; cytostatic; neuroprotective; gastroenteric;
 XX antiviral; antibacterial; anti-HIV; human immunodeficiency virus;
 XX anti-infectivity; cerebroprotective; neurotropic; anticancer; antifungal;
 XX anticonvulsant; tranquilizer; neuroleptic; vasodilator; gynecological;
 XX keratolytic; protozoacide; gene therapy.
 XX
 XX homo sapiens.
 XX
 XX MO200070049-A2.
 XX
 XX 23-NOV-2000.
 XX
 XX 19-MAY-2000; 2000MO-US13975.
 XX
 XX 19-MAY-1999; 99US-0134949.
 XX
 XX 15-JUL-1999; 99US-0144270.
 PR

PR 30-JUL-1999; 99US-0146700.
 PR 04-OCT-1999; 99US-0157508.
 XX
 XX (INCYT) INCYTE GENOMICS INC.
 XX
 XX
 P1 Tang YF, Yue H, Lal P, Burford N, Bandman O, Baughn MR;
 P1 Aizawa Y, Lu DW, Patterson CJ;
 XX WPI: 2001-025021/03.
 DR
 DR N-PSDB: AAC84314.
 PT New human extracellular signaling nucleic acids and polypeptides useful
 PT for diagnosing, treating and preventing infections and
 PT gastrointestinal, neurological, reproductive, and
 PT autoimmune/inflammatory disorders
 PS
 PS Claim 1: Page 97: 114pp: English.
 XX
 CC The invention provides human extracellular signaling molecules (EXCS)
 CC and polynucleotides which identify and encode EXCS. EXCS can be
 CC expressed by standard recombinant methodology. The amino acid and nucleic
 CC acid sequences of EXCS are useful for diagnosing, treating and
 CC preventing infections and gastrointestinal (peptic ulcer, dysphagia,
 CC pancreatitis), neurological (e.g. epilepsy, ischemic cerebrovascular
 CC disease, stroke), reproductive (infertility, ovulatory disorders,
 CC endometriosis), autoimmune/inflammatory (rheumatic arthritis, acquired
 CC immunodeficiency syndrome), hematopoietic (leukemia, lymphoma),
 CC proliferative disorders including cancers (of the breast, adrenal gland,
 CC bone). They may also be used to treat fatal familial insomnia,
 CC nutritional and metabolic diseases of the nervous system, myopathies,
 CC mental disorders (anxiety, schizophrenia, mood), as well as infections
 CC caused by parasites (malaria, leishmania, trypanosoma), viral
 CC (adenovirus, coronavirus, flavivirus), bacterial (e.g. pneumococcus,
 CC diphtheria, pertussis, tetanus, typhoid, tuberculosis), and EXCS
 CC (antibodies), agents. The nucleic acids, polypeptides and antibodies,
 CC agonists, pharmaceutical compositions, and antibodies may also be used
 CC for treating or preventing disorders associated with increased or
 CC decreased expression or activity of EXCS. EXCS polynucleotides may also
 CC be used to detect and quantify gene expression in biopsied tissues in
 CC which expression of EXCS may be correlated with the disease, to determine
 CC the presence of EXCS in a sample, to identify EXCS in a sample, to EXCS
 CC levels during therapeutic intervention, to detect the presence of
 CC associated disorders, as targets in microarray, to generate hybridization
 CC probes, and to detect differences in gene sequences among normal, carrier
 CC or affected individuals. Antibodies may also be used in diagnosing
 CC disorders, in monitoring patients being treated with EXCS agonists,
 CC antagonists or inhibitors. Sequences AAB48057-848082 represent the EXCS
 CC of the invention.
 XX
 XX Sequence 121 AA:
 S0
 Query Match: 80.8%; Score 459; DB 22; Length 121;
 Best Local Similarity 83.0%; Pred. No. 2.3e-44;
 Matches 93; Conservative 3; Mismatches 16; Indels 0; Gaps 0;
 Oy 1 MFGSLFALLAAGVPSLMDLPPRRSARNTIRVSRKLTMTGHPMKSKLSPSSSP 60
 Db 10 MFGSLFALLAAGVPSLMDLPPRRSARNTIRVSRKLTMTGHPMKSKLSPSSSP 69
 Oy 61 GAAPHRSAPROQRQASHDLGLILLKNAAGVLSRPAFOIQRRLVLOLQ 112
 Db 70 GTEPHSIRDTGRIGSHNDLIGILLIKALVASEPAPQIGYRFLVQLK 121
 RESULT 3
 AAB64915 standard; peptide: 32 AA.
 XX ID AAB64915 standard; peptide: 32 AA.
 XX AAB64915:
 XX 06-JUL-1999 (first entry)
 XX

DT	22-JUN-2001 (first entry)
XX	Tachykinins peptide SEQ ID NO:550.
DE	Protection: endogenous therapeutic peptide: peptides; conjugation:
KM	hydroxyl; modification: succinimidyl; aminoaldehyde group; amino-
OS	Homo sapiens.
XX	Synthetic.
XX	WO200069900-A2.
PD	23-NOV-2000.
PF	17-MAY-2000: 2000MO-USJ33576.
PR	17-MAY-1999: 99US-0134406.
PR	10-SEP-1999: 99US-0153406.
PR	13-OCT-1999: 99US-0159783.
PA	(CONM-) CONJUCHEM INC.
PI	Bridon PF, Ezrin AM, Milner PG, Holmes DL, Thibaudau K;
PT	WPI: 2001-112059/12.
PT	Modifying and attaching therapeutic peptides to albumin prevents
PT	peptides degradation, useful for increasing length of in vivo activity
PS	-
XX	Disclosure: Page 380; 73pp; English.
CC	The present invention describes a modified therapeutic peptide (I)
CC	comprising a therapeutically active amino acid region (III) and a
CC	linker region (II) which comprises at least one amino acid bonded to
CC	a less therapeutically active amino acid region (IV) which covalently
CC	bonds with amino/hydroxy/thiol groups on blood components to form a
CC	peptides stabilized therapeutic peptide composed of 3-50 amino acids.
CC	(I) are useful for modifying therapeutic peptides e.g. hormones, growth
CC	factors and neurotransmitters, to protect them from peptidase activity
CC	in vivo for the treatment of various disorders. Endogenous therapeutic
CC	peptides are not suitable as drug candidates as they require frequent
CC	administration and have poor stability in vivo. The present invention
CC	reduces the action of peptides to increase length of activity (half
CC	life) and specificity as bonding to large molecules decreases.
CC	Intracellular uptake and interference with physiological processes.
CC	AAB90829 to AAB92441 represent peptides which can be used in the
CC	exemplification of the present invention.
XX	Sequence 30 AA:
OY	18 LSNDLPEFRASKIRVNSKGLATGHRM 47
DB	I LSPDLPSTRGKILTPSYSLAGLHGM 30
ID	AAU43182 standard: Protein: 190 AA.
XX	AAU43382:
XX	27-FEB-2002 (first entry)
DE	Propionibacterium acnes immunogenic protein #4278.

1	AA074034	standard; protein: 119 AA.
2	AA074034	
3	AA074034	
4	AA074034	
5	AA074034	
6	AA074034	
7	AA074034	
8	AA074034	
9	AA074034	
10	AA074034	
11	AA074034	
12	AA074034	
13	AA074034	
14	AA074034	
15	AA074034	
16	AA074034	
17	AA074034	
18	AA074034	
19	AA074034	
20	AA074034	
21	AA074034	
22	AA074034	
23	AA074034	
24	AA074034	
25	AA074034	
26	AA074034	
27	AA074034	
28	AA074034	
29	AA074034	
30	AA074034	
31	AA074034	
32	AA074034	
33	AA074034	
34	AA074034	
35	AA074034	
36	AA074034	
37	AA074034	
38	AA074034	
39	AA074034	
40	AA074034	
41	AA074034	
42	AA074034	
43	AA074034	
44	AA074034	
45	AA074034	
46	AA074034	
47	AA074034	
48	AA074034	
49	AA074034	
50	AA074034	
51	AA074034	
52	AA074034	
53	AA074034	
54	AA074034	
55	AA074034	
56	AA074034	
57	AA074034	
58	AA074034	
59	AA074034	
60	AA074034	
61	AA074034	
62	AA074034	
63	AA074034	
64	AA074034	
65	AA074034	
66	AA074034	
67	AA074034	
68	AA074034	
69	AA074034	
70	AA074034	
71	AA074034	
72	AA074034	
73	AA074034	
74	AA074034	
75	AA074034	
76	AA074034	
77	AA074034	
78	AA074034	
79	AA074034	
80	AA074034	
81	AA074034	
82	AA074034	
83	AA074034	
84	AA074034	
85	AA074034	
86	AA074034	
87	AA074034	
88	AA074034	
89	AA074034	
90	AA074034	
91	AA074034	
92	AA074034	
93	AA074034	
94	AA074034	
95	AA074034	
96	AA074034	
97	AA074034	
98	AA074034	
99	AA074034	
100	AA074034	

```

XX 19-DEC-1995 (first entry)
DT Bombasin-related peptide.
XX Bombasin: frog; PCR: primer; amplification; probe; prohormone; human;
XX veterinary medicine.
XX Bombina orientalis.
XX
XX Key Location/Qualifiers
XX Cleavage site 43 /note= "prohormone processing site"
XX Cleavage site 47 /note= "prohormone processing site"
XX Cleavage site /note= "prohormone processing site"
XX Cleavage site 60
XX Peptide 45..59 /note= "prohormone processing site"
XX Peptide /note= "SAP bombasin-14, peptide of claim 1"
XX Peptide 49..59 /note= "SAP bombasin-10, peptide of claim 2"
XX
XX US5410018-A.
XX 25-APR-1995.
XX
XX 25-FEB-1994: 94US-0203196.
XX
XX 25-FEB-1994: 94US-0203196.
XX
XX (OREG-) OREGON REGIONAL PRIMATE RES CENT.
XX
XX Barry B. Nagalla S, Spindel ER:
XX WPI: 1995-169632/22.
XX N-PSDB: A0628003.
XX
XX Purified bombasin-related peptide(s) - prepared by recombinant DNA
XX methods
XX
XX Disclosure: Fig 1; 10pp; English.
XX
XX The amino acid sequence of a bombasin-related peptide designated
XX SAP-bombasin-14, the sequence of which is shown in SEQ ID NO. 1,
XX PCR primers A062798-9 and probe A068000. The peptides A067403-2-3
XX (residues 45-59 and 49-59 of the protein) are derived from the prohormone
XX by processing at the Ser-Leu and Lys-Lys residue sequences. The
XX peptides have applications within human and veterinary medicine,
XX especially to treat the diseases or disorders specified in US5217955,
XX WO9402018 and WO9220363.
XX
XX Sequence 119 AA:
XX
Query Match 13.5%; Score 76.5; DB 16; Length 119;
Best Local Similarity 30.3%; Pred. No. 0.6;
Matches 23; Conservative 13; Mismatches 35; Indels 5; Gaps 2;
XX 3 GSLLFALLAGVPLSMDD--PEPRSRASKRIVRSRGKALMGKMKKSLSPSPSP 59
XX | | | | | | | | | | | | | | | | | | | | | | | | | | | |
XX 13 gflfh--lllffslatsscmefvdpnpgglslgslngqwarhngfkakldqndge 70
XX | : : : : : : : : : : : : : : : : : : : : : : : : : :
XX 60 LGTAFTYSLRDRLQI 75
XX 71 mesfaktnvcmraal 86
XX
XX
XX RESULT 8
XX ABG22331 standard; Protein: 517 AA.
XX
XX ABG22331:

```

```

DT 18-FEB-2002 (first entry)
XX
XX Novel human diagnostic protein #22322.
XX
XX Human: chromosome mapping; gene mapping; gene therapy; forensic;
XX food supplement; medical imaging; diagnostic; genetic disorder.
XX
XX Homo sapiens.
XX
XX M0200175067-A2.
XX
XX 11-OCT-2001.
XX
XX 30-MAR-2001: 2001MO-US08631.
XX
XX 31-MAR-2000: 2000US-0540217.
XX
XX 23-AUG-2000: 2000US-0649167.
XX
XX (HVS-) HVS00 INC.
XX
XX Drmanac RT, Liu C, Tang YT:
XX WPI: 2001-639362/73.
XX N-PSDB: AAS86518.
XX
XX New isolated polynucleotide and encoded polypeptides, useful in
XX diagnostics, forensics, gene mapping, identification of mutations
XX responsible for genetic disorders or other traits and to assess
XX biodiversity.
XX
XX Claim 20: SEQ ID NO 52690; 103pp; English.
XX
XX The invention relates to isolated polynucleotide (I) and
XX polypeptide (II) sequences. (I) is useful as hybridisation probes,
XX polymerase chain reaction (PCR) primers, oligomers, and for chromosome
XX gene mapping, and in recombinant production of (II). The sequences tags
XX for identifying expressed genes. (II) is useful in gene therapy techniques
XX to restore normal activity of (II) or to treat disease states involving
XX (II). (II) is useful for generating antibodies against it, detecting or
XX quantitating a polypeptide in tissue, as molecular weight markers and as
XX a food supplement. (II) and its binding partners are useful for treating
XX imaging of sites expressing (II). (I) and (II) are useful for treating
XX diseases and polynucleotide sequences have applications
XX in diagnostics, forensics, gene mapping, identification of mutations
XX responsible for genetic disorders or other traits to assess biodiversity
XX and to produce other types of data and products dependent on DNA and
XX amino acid sequences. ABO00010-AB030377 represent novel human
XX diagnostic amino acid sequences of the invention.
XX
XX The amino acid sequence data for this patent did not appear in the printed
XX edition of the patent. The amino acid sequence is formally deposited
XX at ftp.wipo.int/pub/published_pat_sequences.
XX
XX Sequence 517 AA:
XX
Query Match 13.3%; Score 75.5; DB 22; Length 517;
Best Local Similarity 22.0%; Pred. No. 0.7;
Matches 29; Conservative 18; Mismatches 30; Indels 23; Gaps 5;
XX 7 HFLLAGVPLSMDDPEPRSRASKRIVRSRGKALMGKMKKSLSPSPSPSP 66
XX | : : : : | | | | : : : : : : : : : : : : : : : :
XX 186 hlllslgamp-stphlspefrsrgslslsdg-----flqlaelypaaalvga--- 233
XX
XX 67 SLMDQRQLSLDILGTLILKKALGVSLSPSPPODQYRRL 106
XX | : : : : | | | | : : : : : : : : : : : : : : : :
XX 234 -----rlplsvemgjl---salg---skslmlthkxvl 262
XX
XX
XX RESULT 9
XX AAB8502 standard; Protein: 473 AA.
XX
XX AAB8502:

```

XV		AAR89502:				
XX		10-JUL-1996 (first entry)				
XC		Protein sequence for mediating male fertility. In plants.				
XD		Male fertility; plant; microsporogenesis; tassal development; MS45;				
XE		male; sterile; fertile; transformed plant; female parent;				
XF		hybrid seed.				
XG	Zea mays.					
XH	Key	Location/Qualifiers				
XI	Misc-difference	422				
XJ	/note= "Encoded by TAA"					
XK	Misc-difference	424				
XL	/note= "Encoded by TGA"					
XM	Misc-difference	438				
XN	/note= "Encoded by TAA"					
XP	US5A7B365-A.					
XQ	26-DEC-1995.					
XR	12-JUN-1990:					
XS	90US-0537183.					
XT	02-MAY-1993:					
XU	93US-0103720					
XV	PRI 12-JUN-1990:					
XW	90US-0537183.					
XX	28-OCT-1994:					
XY	94NC-US12444.					
YZ	(PION-) PIONEER HI-BRED INT INC.					
ZA	Albertsen MC, Beach LR, Howard J, Huffman GA:					
ZD	NPI. 1996-057646/06.					
ZE	N-PDB: AAT10928.					
ZF	Nucleic acid encoding a protein critical for male fertility in					
ZG	plants - used to produce plants, esp. maize, that are normally male					
ZH	sterile but can be induced to fertility, esp. for use in hybrid seed					
ZI	production					
ZL	Claim 1: Column 23-24; 27pp: English.					
ZM	This sequence represents a protein sequence which mediates male					
ZN	fertility in plants. This sequence is responsible for one of the					
ZO	steps in microsporangemais, specifically tassal development. The					
ZZ	cDNA encoding this protein was isolated from a tassal derived cDNA					
CC	and was named MS45. The introduction of this cDNA into a plant, pref-					
CA	erably, which is normally male sterile causes it to be fertle. Such					
CX	maize plants may be used as female parents in the production of					
CY	hybird seeds.					
DZ	Sequence 473 AA:					
EZ	Query Match	12.9%	Score 73.5; DB 17; Length 473;			
FZ	Blast Local Similarity	29.2%; Pred No. 7.1;				
GZ	Matches	20; Conservative	11; Mismatches	24; Indels	33; Gaps	5
HZ	I MGSLHLHALLA--GWPL-----SNDPEFRASRIRYSR	37				
OY	i : i i :		i			
Db	30 ifftaalataladnqiglsipslavndvpykhelpeygomaw---	pfnasrflr---t	82			
OY	38 GKMAIGHNGKKSPSSPSLPGLTAHTHSRLDQR.L	73				
Db	: :: : :	:				
OY	gletvegevgpsaelrlql-gsgpggladviv	115				
AD	RESULT 10					
ID	AAW77413 standard: Protein; 473 AA.					

[illegible]

KW	Zea mays; maize; male fertility; MS45; sterile plant; hybrid strain;
RM	breding.
XX	
OS	Zea mays.
PT	Key
FT	Misc-difference 422
FT	/label= unknown
FT	/note= "encoded by TAA (a stop codon)"
FT	Misc-difference 424
FT	/label= unknown
FT	/note= "encoded by TGA (a stop codon)"
FT	Misc-difference 428
FT	/label= unknown
FT	/note= "encoded by TAA (a stop codon)"
PN	US5859341-A.
PX	12-JAN-1999.
PD	
XP	X
XP	7- JUN-1995: 950S-0482714.
PR	02-MAY-1993: 93US-0103729.
PR	12-JUN-1990: 90US-0537183.
PR	07-JUN-1995: 95US-0482714.
PA	(PION-) PIONEER HI-BRED INT INC.
XX	
XX	Albertsen WC, Beach LR, Howard J, Huffman GA;
XX	NPI: 1999-120032/10.
DR	N-PSTB: AAX0048Z.
XX	
PT	Constitutively made sterile plants - with inducible male fertility,
PT	useful in hybrid breeding
XX	
XX	Example 1: Column 33-36; 36pp; English.
CC	A method has been developed of providing heritable, externally
CC	controlled male fertility in plants. The method comprises: (a) cloning a
CC	gene (I) that encodes a product (II) essential for microsporangia;
CC	(b) linking (I) to an expression control sequence that includes an
CC	inducible promoter, responsive to external controls; (c) rendering the
CC	inoperative the native gene that encodes (II); and (d) inserting the
CC	product of (c) into a plant genome so as to produce a fertile transgenic
CC	plant that is constitutively sterile but controllably produces a
CC	sufficient amount of functional product (II) to render the plant
CC	produced by the above method, their parts, cells, and seeds (and any
CC	plants grown from these seeds, their parts and cells), and hybrid seeds
CC	products given these plants. The method produces plants that are useful
CC	in breeding hybrid strains. The method produces plants that are useful
CC	In breeding hybrid strains. The method produces plants that are useful
CC	Plants fertile can tolerate 70-80% failure of induction without a
CC	loss of yield or seed viability. The method produces plants that are useful
CC	methods based on rendering constitutively fertile plants sterile no
CC	manual removal of tassels (from maize plants) is required, and no
CC	treatment with chemicals is needed during hybrid development. The
CC	present sequence represents the MS45 protein isolated from Zea mays In
CC	an example from the present invention.
XX	
XX	Sequence 473 Ab:
SQ	

Oy	Query Match	12.9%	Score 73.5:	DB 20:	Length 473:
Dz	Best Local Similarity	29.2%	Pred. No. 7.1:		
Matches	28:	Conservative	11:	Mismatches	33:
Oy	I MFSGLHALLAA--GVPL-----	SSDLEPSRASKIRVSR	37		
Ox					
Dz	30 GILATLALCHGKSLSPSPSCGTAPMTLDRLT	30 ILSLLYGGHSGNLTSPSPSCGTAPMTLDRLT	73		
Oy	: : : : : : : : :	: : : : : : : :			
Dz	83 grlfvgevrpsjleldiq---grlpygaldqrv	115 grrlfvgevrpsjleldiq---grlpygaldqrv	115		

AA09062	12	AAW90062 standard; Protein; 473 AA.
AC	XX	AAW90062.
AD	XX	04-MAR-1999 (first entry)
AE	XX	Maize MS45 protein.
AF	XX	
AG	XX	Corn; MS45; plant; fertility; gene inactivation; Inducible promoter.
AH	XX	Zea mays.
AI	XX	
AK	XX	Key
AL	XX	Misc-difference 422
AM	XX	Label= unknown
AN	XX	Misc-difference 422
AO	XX	Label= unknown
AP	XX	Misc-difference 438
AQ	XX	/label= unknown
AR	XX	US5850014-A.
AS	XX	15-DEC-1998.
AT	XX	07-JUN-1995; 9505-0485845.
AW	XX	02-MAR-1993; 9308-0103739.
AX	XX	12-JUN-1990; 9008-0537183.
AY	XX	07-JUN-1995; 9508-0485845.
AZ	XX	(PION-1) PIONEER HI-BRED INT INC.
BA	XX	Albertsen MC, Beach LR, Howard J, Huffman GA;
BB	XX	NPI: 1999-094416/08.
BC	XX	N-PSDB; MAW73926.
BD	XX	Non-maize plant containing defined cDNA sequence - and plant
BE	XX	containing defined amino acid sequence
BF	XX	
BG	XX	Claim 2: Column 33-36: 35pp; English.
BH	XX	This sequence represents the maize MS45 protein. This protein is used in
BI	XX	a method critical to the fertility of a plant is controlled by inactivating
BJ	XX	gene linked to an inducible promoter.
BK	XX	
BL	XX	Sequence 473 AA:
BM	XX	
BN	XX	
BO	XX	
BP	XX	
BQ	XX	
BR	XX	
BS	XX	
BT	XX	
BV	XX	
BW	XX	
BX	XX	
BY	XX	
BZ	XX	
CA	XX	
CB	XX	
CC	XX	
CD	XX	
CE	XX	
CF	XX	
CG	XX	
CH	XX	
CI	XX	
CJ	XX	
CK	XX	
CL	XX	
CM	XX	
CN	XX	
CO	XX	
CP	XX	
CQ	XX	
CR	XX	
CS	XX	
CT	XX	
CU	XX	
CV	XX	
CW	XX	
CX	XX	
CY	XX	
CA	XX	
CB	XX	
CC	XX	
CD	XX	
CE	XX	
CF	XX	
CG	XX	
CH	XX	
CI	XX	
CJ	XX	
CK	XX	
CL	XX	
CM	XX	
CN	XX	
CO	XX	
CP	XX	
CQ	XX	
CR	XX	
CS	XX	
CT	XX	
CU	XX	
CV	XX	
CW	XX	
CX	XX	
CY	XX	
CA	XX	
CB	XX	
CC	XX	
CD	XX	
CE	XX	
CF	XX	
CG	XX	
CH	XX	
CI	XX	
CJ	XX	
CK	XX	
CL	XX	
CM	XX	
CN	XX	
CO	XX	
CP	XX	
CQ	XX	
CR	XX	
CS	XX	
CT	XX	
CU	XX	
CV	XX	
CW	XX	
CX	XX	
CY	XX	
CA	XX	
CB	XX	
CC	XX	
CD	XX	
CE	XX	
CF	XX	
CG	XX	
CH	XX	
CI	XX	
CJ	XX	
CK	XX	
CL	XX	
CM	XX	
CN	XX	
CO	XX	
CP	XX	
CQ	XX	
CR	XX	
CS	XX	
CT	XX	
CU	XX	
CV	XX	
CW	XX	
CX	XX	
CY	XX	
CA	XX	
CB	XX	
CC	XX	
CD	XX	
CE	XX	
CF	XX	
CG	XX	
CH	XX	
CI	XX	
CJ	XX	
CK	XX	
CL	XX	
CM	XX	
CN	XX	
CO	XX	
CP	XX	
CQ	XX	
CR	XX	
CS	XX	
CT	XX	
CU	XX	
CV	XX	

DT 13-NOV-2001 (first entry)

XX Amino acid sequence of MS45, a plant male fertility gene.

XX MS45: male fertility gene; sterile plant; fertility.

XX Zea mays.

OS

XX Key Location/Qualifiers

XX FT Misc-difference 422 "encoded by a stop codon"

XX FT Misc-difference 424 "note" "encoded by a stop codon"

XX FT Misc-difference 438 "note" "encoded by a stop codon"

XX FT US6265640-B1.

XX 24-JUL-2001.

XX 10-DEC-1998: 9805-0211416.

XX 09-MAR-1992: 9205-0848433.

XX 02-AUG-1993: 9305-0103739.

XX 07-JUN-1993: 9305-0483845.

XX 21-DEC-1993: 9305-0171302.

XX (P10N-) PIONEER HI-BRED INT INC.

XX Albertsen MC, Beach LR, Howard J, Huffman GA:

XX WPI: 2001-463948/50.

XX M-PSDB: AAH77827.

XX Nucleotide sequences useful for producing plants with inducible fertility/sterility -

XX Disclosure: Column 33-36; 34pp; English.

XX The present sequence represents MS45. MS45 is a plant male fertility gene. Genomic MS45 comprises at least 2.1 kb of DNA from 100-110 base pairs (bp). In length, the MS45 nucleotide sequence may be used to control plant fertility through the production of a constitutively sterile plant in which fertility may be induced. The plants are rendered controllably sterile by using an inducible promoter to regulate expression of the DNA molecule so that the gene is normally "off" and the plant is fertile.

XX Therefore sterile. When the promoter is induced, the plant becomes fertile.

XX Sequence 473 Aa:

SO

Query Match 12.98; Score 73.5; DB 22; Length 473;

Best Local Similarity 29.28; Prod No. 7.1;

Matches 20; Conservative 11; Mismatches 24; Indels 33; Gaps 5;

OY 1 MGSGLALHALLAA--GVVPP-----GMDLPPSPASAKRFBVHSR 37

DB 30 lffanlatalldvdfgblaplaevdypvphkblapvgevgaw-----pdmnaarlr--r 82

OY 38 GKLMATGHPMKKSLSPSSPSPLCTAGTPTSLMDQR 73

DB 83 gletfeygevgfgesldldq--gagpyagladgyv 115

RESULT 14

ABG29063

ID ABG29063 standard; Protein: 969 Aa.

XX

XX ABG29063:

XX

XX 18-FEB-2002 (first entry)

XX Novel human diagnostic protein #29054.

XX Human: chromosome mapping; gene mapping; gene therapy; forensic;

XX Food supplement; medical imaging; diagnostic; genetic disorder.

XX Homo sapiens.

XX W0200175067-A2.

XX 11-OCT-2001.

XX 30-MAR-2001: 2001MO-US08631.

XX 31-MAR-2000: 2000US-0540217.

XX 23-AUG-2000: 2000US-0649167.

XX (HYSE-) HYSEQ INC.

XX Dermanac RT, Liu C, Tang YT:

XX WPI: 2001-63362/73.

XX M-PSDB: AAS93250.

XX New isolated polynucleotide and encoded polypeptides, useful in diagnostics, forensics, gene mapping, identification of mutations for genetic disorders or other traits and to assess biodiversity -

XX Claim 20: SEQ ID No 59422; 103pp; English.

XX The invention relates to isolated polynucleotide (I) and polypeptide (II) sequences. (I) is useful as hybridization probes, for example, in the detection of mutations in the human chromosome 10p11.23 region. (II) is useful as a diagnostic tool in the detection of (I). The polynucleotide sequences are also used in diagnostics as expressed sequence tags for identifying expressed genes. (I) is useful in gene therapy techniques to restore normal activity of (II) or to treat disease states involving (II). (II) is useful for generating antibodies against it, detecting or quantitating a polypeptide in tissue, as molecular weight markers and as a food supplement. (I) and its binding partners are useful in medical diagnostics, forensics, gene mapping, identification of mutations, disorders involving aberrant protein expression or biological activity. The polypeptide and polynucleotide sequences have applications in diagnostics, forensics, gene mapping, identification of mutations and to produce other types of data and products dependent on DNA and amino acid sequences. AAG0010-ABG0377 represent novel human diagnostic amino acid sequences of the invention, appear in the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pcl_sequences.

XX Sequence 969 Aa:

SO

Query Match 12.98; Score 73.5; DB 22; Length 969;

Best Local Similarity 27.18; Prod No. 17;

Matches 26; Conservative 13; Mismatches 34; Indels 23; Gaps 4;

OY 15 VVPLSLDLPEPR-----SHAKSRVHSGMLATGHPMKKSLSPSSPSPLCTA 63

DB 442 mmprrfdlpeqrmgkygrhkhkksctglgtl-ltqslqyqshltnlmpssallshqet 500

OY 64 PHTSLMDQRQLSLDLGTLTKKAKTGVSS-LSPPA 98

DB 501 ph-----yhtcygsllessawapsap 526

RESULT 15

AAAB85555

ID AAAB85555 standard; Protein: 148 Aa.

XX

XX AAAB85555:

XX

AC	AAM9555;
XX	07-NOV-2001 (first entry)
DE	Human Immune/haematopoietic antigen SRQ ID NO:13148.
XX	
XX	Human; Immune; haematopoietic; Immune/haematopoietic antigen; cancer;
XX	Cytotoxic; gene therapy; vaccine; metastasis.
XX	
OS	Homo sapiens.
XX	
PN	MO200157182-A2.
PD	09-AUG-2001.
XX	
XX	17-JAN-2001; 2001MO-US01354.
XX	
PR	31-JAN-2000; 2000US-0179065.
PR	04-FEB-2000; 2000US-0180628.
PR	24-FEB-2000; 2000US-0184654.
PR	02-MAR-2000; 2000US-0186350.
PR	16-MAR-2000; 2000US-0188974.
PR	13-APR-2000; 2000US-0191380.
PR	16-APR-2000; 2000US-0198129.
PR	19-MAY-2000; 2000US-0205515.
PR	07-JUN-2000; 2000US-0209467.
PR	28-JUN-2000; 2000US-0214886.
PR	30-JUN-2000; 2000US-0215135.
PR	07-JUL-2000; 2000US-0216475.
PR	13-JUL-2000; 2000US-0218880.
PR	14-JUL-2000; 2000US-0217486.
PR	14-JUL-2000; 2000US-0218290.
PR	26-JUL-2000; 2000US-0220953.
PR	26-JUL-2000; 2000US-0220954.
PR	14-AUG-2000; 2000US-0224518.
PR	14-AUG-2000; 2000US-0224519.
PR	14-AUG-2000; 2000US-0225214.
PR	14-AUG-2000; 2000US-0225214.
PR	14-AUG-2000; 2000US-0225266.
PR	14-AUG-2000; 2000US-0225267.
PR	14-AUG-2000; 2000US-0225268.
PR	14-AUG-2000; 2000US-0225270.
PR	14-AUG-2000; 2000US-0225447.
PR	14-AUG-2000; 2000US-0225752.
PR	14-AUG-2000; 2000US-0225752.
PR	14-AUG-2000; 2000US-0225759.
PR	18-AUG-2000; 2000US-0226279.
PR	22-AUG-2000; 2000US-0226681.
PR	22-AUG-2000; 2000US-0226868.
PR	22-AUG-2000; 2000US-0227182.
PR	23-AUG-2000; 2000US-0227059.
PR	30-SEP-2000; 2000US-0229257.
PR	01-SEP-2000; 2000US-0229343.
PR	01-SEP-2000; 2000US-0229344.
PR	01-SEP-2000; 2000US-0229345.
PR	05-SEP-2000; 2000US-0229509.
PR	05-SEP-2000; 2000US-0229513.
PR	06-SEP-2000; 2000US-0229519.
PR	06-SEP-2000; 2000US-0230437.
PR	06-SEP-2000; 2000US-0231249.
PR	08-SEP-2000; 2000US-0231243.
PR	08-SEP-2000; 2000US-0231244.
PR	08-SEP-2000; 2000US-0231413.
PR	08-SEP-2000; 2000US-0231414.
PR	08-SEP-2000; 2000US-0232080.
PR	13-SEP-2000; 2000US-0233081.
PR	14-SEP-2000; 2000US-0233387.
PR	14-SEP-2000; 2000US-0233387.
PR	14-SEP-2000; 2000US-0233398.
PR	14-SEP-2000; 2000US-0233400.

[illegible]

